Articles related to CHEMOTHERAPY

DAGO2 produced 3-year overall survival of 52% versus 35% with CPX-351 in older patients with non-adverse-risk AML in a 439-patient randomized comparison.

“The SunRISe-2 trial was stopped in advance for futility based on week-18 overall response rate assessment and the totality of the efficacy data. However, the CR rates in both arms are compelling.” — Andrea Necchi, MD, ASCO GU Symposium 2026

“Patients treated in the Optune Pax arm had a median time to pain progression of 15.2 months compared to 9.1 months.” — PANOVA-3 Trial, FDA Approval Announcement

“The damage to DNA lasts a lifetime. Probably the biggest concern is the increased risk of other cancers developing as a result of exposure to prior chemotherapy.”

Final analysis confirms venetoclax plus modified intensive chemotherapy achieves durable remissions with 17.9-month treatment-free intervals in fit elderly AML patients, particularly those with de novo disease.

Experts note that the use of chemotherapy can indicate cancer spread beyond its origin, potentially reflecting the stage, aggressiveness, or progression potential of the disease.